Horsham, PA – According to filings with the U.S. Securities and Exchange Commission, Palladio Biosciences is raising $36,483,500.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Alex Martin played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Palladio Biosciences

Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney. Our first product, lixivaptan, is in Phase 3 development for the treatment of polycystic kidney disease (PKD). PKD is one of the most common, life-threatening genetic diseases. PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. PKD is the 4th leading cause of kidney failure and carries a significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan to address the continuing unmet needs of patients, as a safe and effective agent to be used chronically to prevent the progression of PKD.

To learn more about Palladio Biosciences, visit http://palladiobio.com/

Contact:
Alex Martin, Chief Executive Officer
610-256-2806
https://www.linkedin.com/in/johnalexmartin/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved